Tag Archives: Roche

Roche Ups the Stakes on Personalized Medicine

By Guest Blogger | Published: February 1, 2012
By Patricia Van Arnum, Pharmaceutical Technology. Personalized medicine, which targets individualized treatment and care based on personal and genetic variations, holds much promise for the pharmaceutical industry. Several pharmaceutical majors continue to invest in this emerging field as evident by Roche’s $5.7-billion bid last week for Illumina, a provider of gene-sequencing tools and related analytics.
Posted in Biotech, Europe, Global, Guest Blog | Also tagged , | Leave a comment

Genentech Runs Voluntary Corrective Ads for Boniva

By Ben Comer | Published: January 18, 2012
Even though Roche-owned Genentech wasn’t required to run costly corrective advertisements following an FDA Untitled Letter on Boniva last January, the company has done so anyway.
Posted in Advertising, Corporate Responsibility, FDA, Legal, Marketing, Regulatory, compliance, leadership | Also tagged , , | Leave a comment

Roche Gets Tough on Greece

By Julian Upton | Published: September 21, 2011
Roche Gets Tough on Greece, Other Eurozone Countries May Follow On Friday Roche confirmed it had come to the end of its tether with state-funded hospitals in Greece. In an interview with the Wall Street Journal, CEO Severin Schwan announced that the company has increased shipments of drugs to pharmacies in the country, while cutting off [...]
Posted in Global, healthcare | Also tagged , , , , | Leave a comment

Roche Joins the Roll Call of Pharma Layoffs

By Julian Upton | Published: November 17, 2010
So, Roche is the latest industry giant to announce seismic job cut plans — 6 percent of its global workforce — or 4800 jobs — will go by 2012.  The Swiss company aims to generate annual cost saving of 2.4 billion Swiss francs in the process. But don’t be swayed by the European currency — [...]
Posted in Europe, Global, Strategy | Also tagged , | 1 Comment

Advisory Panel Rejects Avastin For Breast Cancer Treatment

By George Koroneos | Published: July 21, 2010
An FDA advisory panel on Tuesday voted 12–1 to discontinue Avastin (bevacizumab) as a treatment for advanced breast cancer due to post-market studies stating that the treatment does not to increase patient lifespan by any significant length of time. This is a huge problem for Roche who purchased the treatment as part of its merger with [...]
Posted in FDA, Safety | Also tagged , , , , , , , | 1 Comment